Abstract
Children who had initially received three doses of either a nonavalent pneumococcal conjugate vaccine containing serotypes 1, 4, 5, 6B, 9V, 14, 18C, 19F, and 23F or placebo at 6, 10, and 14 weeks of age were bled at 9 and 18 months for determination of antibody concentrations. The children were then randomized to receive a booster dose of either the 9-valent pneumococcal conjugate vaccine or a 23-valent polysaccharide vaccine and antibody levels determined 1 month later. At 9 months, the geometric mean concentrations (GMCs) were significantly higher for all vaccine serotypes in vaccinated children compared with controls (means varied from 0.49 microg/ml for serotype 4 to 2.37 microg/ml for serotype 14). At 18 months, antibody concentrations remained significantly higher in vaccinated children (means varied from 0.19 microg/ml for serotype 4 to 1.1 microg/ml for serotype 14). In children who had received conjugate vaccine in infancy, the conjugate vaccine at 18 months produced a significant booster response for serotypes 1, 6B, 14, 19F, and 23F (means varied from 2.74 microg/ml for serotype 19F to 15.52 microg/ml for serotype 6B) and produced a comparable response to a first dose of conjugate at this age for serotypes 4, 5, 9V, ...Continue Reading
References
Mar 18, 1992·JAMA : the Journal of the American Medical Association·Y Schlesinger, D M Granoff
Apr 1, 1996·The Pediatric Infectious Disease Journal·A LeachB M Greenwood
Apr 29, 1998·Pediatrics·M B RennelsA Kimura
Apr 16, 1998·The Pediatric Infectious Disease Journal·H AhmanJ Eskola
Jun 2, 1998·The Journal of Infectious Diseases·M AnttilaH Käyhty
Apr 27, 1999·Vaccine·M AnttilaH Käyhty
May 6, 1999·The Journal of Infectious Diseases·P RichmondK Cartwright
Sep 9, 1999·The Journal of Infectious Diseases·N MbelleK P Klugman
Sep 24, 1999·The Pediatric Infectious Disease Journal·H R ShinefieldJ Hansen
Jan 5, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·W P HausdorffG R Siber
Feb 29, 2000·The Pediatric Infectious Disease Journal·G CampagneJ P Chippaux
Apr 5, 2000·The Pediatric Infectious Disease Journal·S BlackK Edwards
Oct 24, 2001·Vaccine·R M OlanderJ Eskola
Citations
Jan 31, 2007·Infection and Immunity·Nina EkströmHelena Käyhty
Feb 12, 2010·BMC Infectious Diseases·Bradford D GessnerSeydou Yaro
Sep 29, 2006·The Pediatric Infectious Disease Journal·Mark J AbzugUNKNOWN Pediatric AIDS Clinical Trials Group P1024 Protocol Team
Jun 2, 2009·The Pediatric Infectious Disease Journal·Marilla G LuceroHelen P Mäkelä
Sep 13, 2011·The Pediatric Infectious Disease Journal·Markus KnufLode Schuerman
Apr 21, 2012·Current Opinion in Infectious Diseases·Ray BorrowClaire-Anne Siegrist
Sep 4, 2012·Vaccine·Shabir A MadhiAnne von Gottberg
Mar 9, 2010·Vaccine·F M RussellE K Mulholland
May 12, 2009·Vaccine·Anu SoininenUNKNOWN ARIVAC Consortium
Aug 24, 2007·The Lancet Infectious Diseases·Katherine L O'BrienDavid Goldblatt
Oct 28, 2006·Immunology·Elizabeth A ClutterbuckAndrew John Pollard
Oct 31, 2006·Vaccine·Jens U RuggebergPaul T Heath
Nov 27, 2014·Human Vaccines & Immunotherapeutics·Usa ThisyakornSunate Chuenkitmongkol
Mar 5, 2010·Vaccine·F M RussellE K Mulholland
Apr 21, 2016·The Pediatric Infectious Disease Journal·Menno R van den BerghElisabeth A M Sanders
May 10, 2013·Clinical and Vaccine Immunology : CVI·Nina EkströmUNKNOWN FinOM Study Group
Jan 30, 2007·Clinical Chemistry·Axel JeurissenXavier Bossuyt
Oct 8, 2005·Clinical and Diagnostic Laboratory Immunology·Kathryn T BiegingSandra Romero-Steiner